ZA201807438B - Methods of treating ocular conditions - Google Patents

Methods of treating ocular conditions

Info

Publication number
ZA201807438B
ZA201807438B ZA2018/07438A ZA201807438A ZA201807438B ZA 201807438 B ZA201807438 B ZA 201807438B ZA 2018/07438 A ZA2018/07438 A ZA 2018/07438A ZA 201807438 A ZA201807438 A ZA 201807438A ZA 201807438 B ZA201807438 B ZA 201807438B
Authority
ZA
South Africa
Prior art keywords
methods
treating ocular
ocular conditions
conditions
treating
Prior art date
Application number
ZA2018/07438A
Other languages
English (en)
Inventor
James Loudin
Jr Douglas Michael Ackermann
Kenneth J Mandell
Original Assignee
Oyster Point Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oyster Point Pharma Inc filed Critical Oyster Point Pharma Inc
Publication of ZA201807438B publication Critical patent/ZA201807438B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA2018/07438A 2016-04-07 2018-11-06 Methods of treating ocular conditions ZA201807438B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662319648P 2016-04-07 2016-04-07
PCT/US2017/026385 WO2017177024A1 (en) 2016-04-07 2017-04-06 Methods of treating ocular conditions

Publications (1)

Publication Number Publication Date
ZA201807438B true ZA201807438B (en) 2024-09-25

Family

ID=58549326

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/07438A ZA201807438B (en) 2016-04-07 2018-11-06 Methods of treating ocular conditions

Country Status (19)

Country Link
US (3) US10709707B2 (cg-RX-API-DMAC10.html)
EP (2) EP3970724A1 (cg-RX-API-DMAC10.html)
JP (3) JP7090551B2 (cg-RX-API-DMAC10.html)
KR (2) KR102512777B1 (cg-RX-API-DMAC10.html)
CN (3) CN114533737B (cg-RX-API-DMAC10.html)
AU (1) AU2017248276B2 (cg-RX-API-DMAC10.html)
DK (1) DK3439661T3 (cg-RX-API-DMAC10.html)
EA (1) EA201892265A1 (cg-RX-API-DMAC10.html)
ES (1) ES2893126T3 (cg-RX-API-DMAC10.html)
IL (3) IL299204A (cg-RX-API-DMAC10.html)
MX (2) MX385698B (cg-RX-API-DMAC10.html)
MY (1) MY199237A (cg-RX-API-DMAC10.html)
NZ (1) NZ746468A (cg-RX-API-DMAC10.html)
PH (1) PH12018502154A1 (cg-RX-API-DMAC10.html)
PT (1) PT3439661T (cg-RX-API-DMAC10.html)
SG (1) SG11201808650QA (cg-RX-API-DMAC10.html)
TW (2) TWI876258B (cg-RX-API-DMAC10.html)
WO (1) WO2017177024A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201807438B (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
CN107106542B (zh) 2014-10-20 2020-05-08 奥伊斯特普安生物制药公司 治疗眼部病状的方法
NZ746468A (en) * 2016-04-07 2023-06-30 Oyster Point Pharma Inc Methods of treating ocular conditions
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
EP4142734B1 (en) * 2020-04-28 2025-08-20 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
JP2024517459A (ja) * 2021-05-07 2024-04-22 オイスター ポイント ファーマ インコーポレイテッド ベクター及びニコチン作動薬の併用療法
WO2026080563A1 (en) 2024-10-09 2026-04-16 Oyster Point Pharma, Inc. Simpinicline oral formations and use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
IL161326A0 (en) 2001-11-29 2004-09-27 Pfizer Prod Inc Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof
AU2003269413A1 (en) 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
US20060270592A1 (en) 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
EP1802276A1 (en) 2004-10-15 2007-07-04 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
US20090023819A1 (en) 2005-03-22 2009-01-22 Anders Axelsson Use of an Artificial Sweetener to Enhance Absorption of Nicotine
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
TWI405763B (zh) 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
DK2114970T3 (da) 2007-02-02 2011-09-19 Pfizer Prod Inc Tricykliske forbindelser og deres anvendelse som glucocorticoidreceptormodulatorer
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
US20090093446A1 (en) 2007-10-05 2009-04-09 Winston Laboratories, Inc. Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
US20110071180A1 (en) 2008-03-05 2011-03-24 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
JP2012502039A (ja) 2008-09-05 2012-01-26 ターガセプト，インコーポレイテッド ジアザビシクロオクタンのアミド及びその用途
AU2009303545A1 (en) * 2008-10-14 2010-04-22 Psychogenics, Inc Nicotinic acetylcholine receptor ligands and the uses thereof
IL266097B (en) * 2008-12-01 2022-07-01 Oyster Point Pharma Inc Mono-orotate acid addition salt of r(–5–)–e(–2–)pyrrolidine––3ylvinyl)pyrimidine
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
TW201024283A (en) 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
RU2012101424A (ru) * 2009-06-17 2013-07-27 Таргасепт, Инк. Устранение l-дофа-индуцированной дискинезии с помощью лигандов нейрональных никотиновых рецепторов
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8821457B2 (en) 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
IN2014CN03647A (cg-RX-API-DMAC10.html) 2011-10-20 2015-10-09 Novartis Ag
US20140357971A1 (en) 2011-11-30 2014-12-04 Diagnostear Ltd. Dry eye diagnostic
CN107106542B (zh) 2014-10-20 2020-05-08 奥伊斯特普安生物制药公司 治疗眼部病状的方法
NZ746468A (en) 2016-04-07 2023-06-30 Oyster Point Pharma Inc Methods of treating ocular conditions

Also Published As

Publication number Publication date
JP2024103594A (ja) 2024-08-01
KR20190005859A (ko) 2019-01-16
US20190201397A1 (en) 2019-07-04
CN114533737B (zh) 2024-05-31
PH12018502154A1 (en) 2019-07-08
US10709707B2 (en) 2020-07-14
WO2017177024A8 (en) 2018-11-08
DK3439661T3 (da) 2021-10-18
TWI790997B (zh) 2023-02-01
MX2018012230A (es) 2019-03-28
CN109310692A (zh) 2019-02-05
TW201737917A (zh) 2017-11-01
ES2893126T3 (es) 2022-02-08
KR102512777B1 (ko) 2023-03-23
EP3439661A1 (en) 2019-02-13
IL290069B1 (en) 2023-01-01
AU2017248276A1 (en) 2018-11-22
US20250000861A1 (en) 2025-01-02
JP2019513759A (ja) 2019-05-30
WO2017177024A1 (en) 2017-10-12
EP3970724A1 (en) 2022-03-23
ES2893126T8 (es) 2022-05-23
MX385698B (es) 2025-03-18
TWI876258B (zh) 2025-03-11
CN114432313A (zh) 2022-05-06
EP3439661B1 (en) 2021-08-04
IL299204A (en) 2023-02-01
IL290069A (en) 2022-03-01
EA201892265A1 (ru) 2019-04-30
PT3439661T (pt) 2021-09-30
IL290069B2 (en) 2023-05-01
CN114533737A (zh) 2022-05-27
BR112018070497A2 (pt) 2019-01-29
NZ785093A (en) 2024-07-05
JP7090551B2 (ja) 2022-06-24
TW202320785A (zh) 2023-06-01
MX2021010399A (es) 2022-01-18
IL262102B (en) 2022-03-01
SG11201808650QA (en) 2018-10-30
MY199237A (en) 2023-10-22
CN109310692B (zh) 2022-01-25
JP2022120125A (ja) 2022-08-17
US20200345734A1 (en) 2020-11-05
IL262102A (en) 2018-11-29
NZ746468A (en) 2023-06-30
AU2017248276B2 (en) 2023-07-13
CA3020170A1 (en) 2017-10-12
KR20230010813A (ko) 2023-01-19
KR102485299B1 (ko) 2023-01-06

Similar Documents

Publication Publication Date Title
GB2541571A (en) Pharmaceutical compositions
PH12018502154A1 (en) Methods of treating ocular conditions
SA519401246B1 (ar) (r) صياغات من-2- أمينو-3- فينيل بروبيل كربامات
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2024013018A (es) Dianas terapeuticas para la correccion del gen de la distrofina humana por edicion genica y metodos de uso
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2018011114A (es) Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
ZA201703467B (en) Methods of treating ocular conditions
PH12019501097A1 (en) Magl inhibitors
EA201791095A1 (ru) Способ лечения рака
PH12019501102A1 (en) Magl inhibitors
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
EA201800565A1 (ru) Композиция для лечения заболеваний уха, содержащая (+)-азасетрон
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
EP3302382A4 (en) IMPLANT FOR THE TREATMENT OF OCULAR DISEASE
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.
EP3402531A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
EA201692164A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
HK1262958A1 (en) Compositions and methods for treatment of eye diseases